CELF4: A Potential Drug Target and Biomarker (G56853)

Target Name: CELF4

NCBI ID: G56853

CELF4

CELF4: A Potential Drug Target and Biomarker

Introduction

CELF4 (cluster-related gene 4) is a gene that encodes a protein known as Brucella phagocyticum flagellin. Brucellin is a protein secreted by the bacterium Brucella that triggers an immune response and causes disease in the body. The protein encoded by the CELF4 gene has a variety of biological functions, such as cell adhesion, signal transduction, and immune regulation. In recent years, researchers have conducted in-depth studies on the function of the CELF4 gene and discovered its potential role in drug development and disease diagnosis.

drug discovery

CELF4's importance as a drug target stems from its role in disease. Brucella infection is a serious illness that can cause persistent joint pain, reproductive problems, skin rashes and rashes, and more. At the same time, brucellins can also cause immune system abnormalities and increase the risk of cardiovascular disease, diabetes, and cancer. Therefore, CELF4 has become a potential drug target.

Currently, drug research targeting CELF4 mainly focuses on the following aspects:

1. Anti-infective drugs: drugs targeting Brucella infection, such as antibiotics, antimalarial drugs and anti-brucellosis drugs. Although these drugs are effective in treating Brucella infections, they do not cure the disease and may lead to the development of drug resistance. Therefore, researchers are working hard to develop new anti-infective drugs to reduce the development of drug resistance and improve treatment efficacy.

2. Immunomodulatory drugs: CELF4 plays a key role in the immune system. Therefore, researchers are exploring CELF4 as a target for immunomodulatory drugs. By inhibiting the function of CELF4, immune system activation can be reduced, thereby reducing inflammation and disease progression. Currently, some drugs, such as antimalarials and immunosuppressants, have been shown to inhibit the function of CELF4 and are used to treat related diseases.

3. Disease diagnosis: The application of CELF4 in disease diagnosis has also attracted much attention. Since brucellin can trigger an immune response, it is possible to determine whether a patient is infected with Brucella by detecting the expression level of CELF4. In addition, the gene expression level of CELF4 can also be used as a biomarker for certain diseases, such as cirrhosis and liver cancer. Therefore, the application of CELF4 in disease diagnosis has great potential.

Biomarkers

The protein encoded by the CELF4 gene can serve as a biomarker for Brucella infection. Studies have found that the expression level of CELF4 can increase with the severity of Brucella infection. In addition, the expression level of CELF4 can also be used as a biomarker for diseases such as cirrhosis and liver cancer. These findings provide a theoretical basis for the application of CELF4 in disease diagnosis.

Clinical application

Currently, the application of CELF4 in drug development and disease diagnosis is still in the exploratory stage. However, existing studies have shown that CELF4 has great potential as a drug target. In the future, with the continuous advancement of technology, the application of CELF4 in drug development and disease diagnosis will be further developed.

in conclusion

CELF4 is a gene with potential as a potential drug target. By inhibiting the function of CELF4, Brucella infections can be treated and used for disease diagnosis. At present, the application of CELF4 in drug development and disease diagnosis is still in the exploratory stage, but research on CELF4 as a drug target has achieved certain results. With the continuous advancement of technology, the application of CELF4 in drug development and disease diagnosis will be further developed.

Protein Name: CUGBP Elav-like Family Member 4

Functions: RNA-binding protein implicated in the regulation of pre-mRNA alternative splicing. Mediates exon inclusion and/or exclusion in pre-mRNA that are subject to tissue-specific and developmentally regulated alternative splicing. Specifically activates exon 5 inclusion of cardiac isoforms of TNNT2 during heart remodeling at the juvenile to adult transition. Promotes exclusion of both the smooth muscle (SM) and non-muscle (NM) exons in actinin pre-mRNAs. Activates the splicing of MAPT/Tau exon 10. Binds to muscle-specific splicing enhancer (MSE) intronic sites flanking the alternative exon 5 of TNNT2 pre-mRNA

The "CELF4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CELF4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets